We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.62B
1-Year Est. Return
138.67%
This Fund
S&P 500
This Quarter
Est. Return
+14.49%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$187M
AUM Growth
–
Cap. Flow
+$207M
Cap. Flow
% of AUM
110.8%
Top 10 Holdings %
Top 10 Hldgs %
68.58%
Holding
32
New
32
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$30.8M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$20M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$17.7M |
| 4 |
Gossamer Bio
GOSS
|
+$12.1M |
| 5 |
Biogen
BIIB
|
+$10.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $29.1M | 15.54% |
+992,949
| New | +$30.8M |
|
|
2
Xenon Pharmaceuticals
XENE
$6.32B
| $20.9M | 11.19% |
+670,093
| New | +$20M |
|
|
3
Syndax Pharmaceuticals
SNDX
$1.84B
| $20.9M | 11.19% |
+956,165
| New | +$17.7M |
|
|
4
Gossamer Bio
GOSS
$66.5M
| $11.5M | 6.15% |
+1,016,857
| New | +$12.1M |
|
|
5
Biogen
BIIB
$29.9B
| $9.6M | 5.13% |
+40,000
| New | +$10.3M |
|
6
Celldex Therapeutics
CLDX
$2.77B
| $8.76M | 4.68% |
+226,726
| New | +$9.88M |
|
|
AMRN
7
Amarin Corp
AMRN
$284M
| $7.45M | 3.98% |
+110,543
| New | +$9.15M |
|
8
Vera Therapeutics
VERA
$2.54B
| $6.77M | 3.62% |
+253,449
| New | +$5.61M |
|
9
Liquidia Corp
LQDA
$7.67B
| $6.66M | 3.56% |
+1,366,836
| New | +$5.45M |
|
|
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
| $6.63M | 3.54% |
+573,699
| New | +$6.39M |
|
11
Viridian Therapeutics
VRDN
$2.13B
| $5.69M | 3.04% |
+287,934
| New | +$5.36M |
|
12
Travere Therapeutics
TVTX
$5.33B
| $5.65M | 3.02% |
+182,103
| New | +$5.13M |
|
13
Fate Therapeutics
FATE
$281M
| $5.59M | 2.99% |
+95,561
| New | +$5.42M |
|
14
Vaxcyte
PCVX
$7.89B
| $5.03M | 2.69% |
+211,483
| New | +$4.92M |
|
15
Wave Life Sciences
WVE
$1.12B
| $4.69M | 2.51% |
+1,494,594
| New | +$6.21M |
|
|
MRUS
16
DELISTED
Merus
MRUS
| $3.88M | 2.08% |
+122,158
| New | +$3.45M |
|
|
BNR
17
Burning Rock Biotech
BNR
$94.4M
| $3.65M | 1.95% |
+38,246
| New | +$5.24M |
|
|
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
| $3.34M | 1.79% |
+205,800
| New | +$3.02M |
|
19
Olema Pharmaceuticals
OLMA
$1.02B
| $2.75M | 1.47% |
+293,799
| New | +$6.09M |
|
|
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
| $2.69M | 1.44% |
+239,041
| New | +$3.22M |
|
21
Seres Therapeutics
MCRB
$48M
| $2.54M | 1.36% |
+15,245
| New | +$2.42M |
|
22
Cabaletta Bio
CABA
$439M
| $2.44M | 1.31% |
+644,583
| New | +$6.88M |
|
23
Krystal Biotech
KRYS
$9.88B
| $2.44M | 1.3% |
+34,816
| New | +$2.03M |
|
24
Puma Biotechnology
PBYI
$406M
| $2.08M | 1.11% |
+683,619
| New | +$2.97M |
|
|
AFMD
25
DELISTED
Affimed
AFMD
| $2.01M | 1.07% |
+36,403
| New | +$2.25M |
|
Similar funds
IPW
WIC
HH
TLFA
KCM
PRA
BW
CC
Kynam Capital Management's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for Kynam Capital Management, which disclosed 32 positions worth $187M. Its ten largest holdings account for 69% of the portfolio.
Its largest position is Global Blood Therapeutics, Inc.: 992,949 shares worth $29.1M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets.
- Kynam Capital Management's largest Q4 2021 buy was Global Blood Therapeutics, Inc.: 992,949 shares worth $29.1M.
- Kynam Capital Management's ten largest holdings make up 69% of its $187M portfolio in Q4 2021.
- Kynam Capital Management disclosed 32 positions in Q4 2021, its first 13F filing on record.
Based on Kynam Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.